Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

Prior treatment

• Individuals with contraindications to conservative treatment or medication use
• Patients who have taken other types of antihypertensive drugs regularly in the past

Other illness

• Merge malignant tumors from other parts

Other

• Tumor invasion of muscle layer\>1/2, FIGO (2009) stage IB or above
• Tumor differentiation into G3 or non endometrioid adenocarcinoma
• Patients known to have experienced hypotension

• Pathological diagnosis of endometrial adenocarcinoma G1-2 of the endometrium
• If the pathology is endometrial cancer, MRI or ultrasound confirms that the lesion is limited to the endometrium or invading the muscle\<1/2, that is, FIGO (2009) stage IA
• Age ≤ 45 years old
• Require those who wish to retain their reproductive function to sign informed consent
• No serious internal medicine complications (severe liver and kidney dysfunction)
• No contraindications for progesterone treatment or pregnancy
• Has not experienced hypotension more than three times in the past six months and can be regularly monitored for blood pressure
• Imaging shows no evidence of distant metastasis
• A. Initial treatment patients: have not used any protective treatment drugs (progestogens, GNRH-a); B. One course of treatment (12 weeks) with incomplete remission of the lesion (partial remission, persistent or progressive lesion); C. Two courses of treatment (24 weeks) with incomplete remission (partial remission, persistent or progressive lesions);